研究单位：[1]Pfizer[2]Dongguan People's Hospital,Dongguan,Guangdong,China,523059[3]Affiliated Hospital of Hebei University,Baoding,Hebei,China,071000[4]Jinan Central Hospital,Jinan,Shandong,China,250013[5]Tianjin Medical University General Hospital,Tianjin,Tianjin,China,300052
研究目的：
The current study will compare the efficacy, safety, pharmacokinetics and immunogenicity of PF-06439535 (CN) in combination with paclitaxel and carboplatin versus bevacizimab sourced from the European Union (bevacizumab-EU) with paclitaxel and carboplatin in Chinese participants with advanced non-squamous NSCLC in the first-line treatment setting.
